SynthesisBMC infectious diseases2026
Global mapping of bedaquiline-resistant Mycobacterium tuberculosis: a systematic review.
Synthesis in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTuberculosis (TB) is one of the deadliest bacterial infectious diseases worldwide, with rising cases of multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains. Bedaquiline (BDQ)-containing regimens have become important for the treatment of MDR/XDR-TB, and resistance to BDQ is increasing. Understanding genetic mutations is crucial for early detection of BDQ-resistant strains and thus maintaining the effectiveness of these drugs. This study aimed to review mutations associated with BDQ-resistant TB globally.
methodsThis study systematically searched the keywords TB, XDR, MDR, BDQ, and genes in the PubMed, Scopus, Web of Science, and Embase databases for studies reporting BDQ-resistant TB and their associated genes globally from 2014 to 2025.
resultsThis systematic review included 40 studies and 25,234 patient samples with MDR and XDR-TB from around the world. Results showed significant variation in BDQ resistance across the World Health Organization (WHO) regions, with the highest in the Eastern Mediterranean and the lowest in the Western Pacific. Furthermore, the data collected showed that, among the continents studied, resistance was highest in Africa and lowest in the Americas. The country distribution showed that resistance rates were higher in Iran (n = 24), Moldova (n = 26), and Armenia (n = 35), and lower in Italy (n = 1001) and the Philippines (n = 724) than in other countries in the analysis. Genetically, the most resistance-associated mutations were observed in the Rv0678, atpE, and pepQ genes, respectively.
conclusionGiven the increasing BDQ resistance and regional variability, it is essential to develop early detection systems, genomic surveillance, robust drug policy enforcement, and rapid diagnostics to maintain treatment effectiveness and curb the spread of resistance. Future research should focus on elucidating resistance mechanisms and developing novel therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.